辛伐他汀对急性冠脉综合征患者血清hs-CRP和妊娠相关血浆蛋白-A水平的影响

目的：探讨辛伐他汀对急性冠脉综合征（ACS）患者血清高敏C反应蛋白（hs-CRP）及妊娠相关血浆蛋白-A（PAPP-A）水平的影响。方法：86例ACS患者随机分为观察组（n=43）与对照组（n=43），对照组给予常规治疗，观察组在对照组基础上加用辛伐他汀治疗，对比两组患者总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）水平变化及血清hs-CRP、PAPP-A变化。结果：两组患者治疗4周后TC、LDL-C均显著降低（P〈0．05），且观察组治疗4周后TC显著低于对照组（P〈0．05），而TG、HDLC均未见明显变化（P〉0．05）；治疗1周后两组患者hs-CRP及PAPP-A均显著降低（P〈0．01），且治疗后观察组显著低于对照组（P〈0．01）。结论：辛伐他汀在ACS治疗中能够有效改善患者血脂水平，减轻全身炎性反应，增强冠状动脉粥样硬化斑块的稳定性，降低患者心血管不良事件风险。

Influence of simvastatin on hs-ORP and PAPP-A of patients with acute coronary syndrome

Objective. To explore the influence of simvastatin on hs-CRP and PAPP-A in patients with acute coronary syndrome （ACS）. Methods- 86 patients with ACS were randomly divided into the ob- servation group （n=43） and the control group （n=43）. Patients in the control group were treated with conventional therapy, the observation group were treated with simvastatin based on convention treatment. TC, TG, LDL-C, HDL-C, hs-CRP, and PAPP-A were detected and compared between the two groups.Results： TC and LDL-C were significantly lower 4 weeks after the treatment than before in the two groups （P〈0.05）, and TC in the observation group 4 weeks after the treatment was significantly lower than the control group（P〈0.05）, but there was no significantly difference in TG or HDL-C（P〉0.05）. Hs-CRP and PAPP-A were significantly lower than before 1 week after the treatment in the two groups（P〈0.01）, and the observation group were significantly lower than the control group（P〈0.01）. Conclusions. Simv- astatin can effectively improve the blood lipid levels in patients with ACS, reduce the systemic inflammato- ry response, enhancethe stability of atherosclerotic plaques in coronary arteries, and reduce the risk of car- diovascular adverse events.